References
[1]. Allen, J.L., Liu, X., Weston, D., Conrad, K., Oberdörster,
G., & Cory-Slecta, D.A. (2014). “Consequences of
developmental exposure to concentrated ambient
ultrafine particle air pollution combined with the adult
paraquat and maneb model of the Parkinson's disease
phenotype in male mice.” NeuroToxicology, Vol.41, pp.80-
88.
[2]. Alzheimer's Society. (2014). Diagnosing dementia.
London.
[3]. Bonakis, A., Economou, N., Paparrigopoulos, T.,
Bonanni, E., Maestri, M., Carnicelli, L., et al. (2013). “Sleep
in frontotemporalfementia is equally or possibly more
Ddsrupted, and at an earlier stage, when compared to
sleep in Alzheimer's disease.” Journal of Alzheimer's
Disease, Vol.38, No.1, pp.85-91.
[4]. Cai, W., Uribarri, J., Zhu, L., Chen, X., Swamy, S., Zhao, Z
et al. (2013). Oral glycotoxins are a modifiable cause of
dementia and the metabolic syndrome in mice and
humans. Proceeding of the National Academy of
Sciences of the United States of America.
[5]. Chaudhuri, K.R. & Schapira, A.H. (2009). “Non-motor
symptoms of Parkinson's disease: dopaminergic
pathophysiology and treatment.” Lancet Neurology, Vol.8,
No.5, pp.464-474.
[6]. Clegg, A., Young, J., Iliffe, S., Rikkert, M.O. &
Rockwood, K. (2013). “Frailty in elderly people.” The Lancet,
Vol.381, No.9868, pp.756-762.
[7]. Costa, L.G., Cole, T.B., Coburn, J., Chang, Y., Dao, K., &
Roque, P. (2014). “Neurotoxicants are in the air:
Convergence of human, animal, and in vitro studies on the
effects of air pollution on the brain.” BioMed Research
International, pp.1-8.
[8]. Davie, C.A. (2008). “A review of Parkinson's disease.”
British Medical Bulletin, Vol.86, pp.09-127.
[9]. DeMunter, J.P.J.M., Melamed, E., &Wolters, E.C. (2014).
“Stem cell grafting in parkinsonism – Why, how and when.”
Parkinsonism & Related Disorder, Vol.20, No.1, pp.150-153.
[10]. Dibble, L.E., & Addison, O., & Papa, E. (2009). “The
effects of exercise on balance in persons with Parkinson's
disease: a systematic review across the disability spectrum.” Journal of Neurologic Physical Therapy, Vol.33,
No.1, pp.14-26.
[11]. Duncan, G.W., Yarnall, A.J., Firbank, , M.J., Barker,
R.A., O'Brien, J.T., & Burn, D.J. (2013). “Grey matter and CSF
amyloid in early non–demented Parkinson's disease: The
incidence of cognitive impairment in cohorts with
longitudinal evaluation in Parkinson's disease (ICICLE–PD)
study.” Journal of Neurology, Neurosurgery & Psychiatry,
Vol.84, No.11.
[12]. Earhart, G.M. (2009). “Dance as therapy for
individuals with Parkinson Disease.” European Journal of
Physical and Rehabilitation Medicine, Vol.45, No.2,
pp.231-38.
[13]. Gardner, R.C., & Yaffe, K. (2014). “Traumatic brain
injury may increase risk of young onset dementia.” Annals
of Neurology, pp.1-3.
[14]. Goldman, S.M. (2014). “Environmental toxins and
Parkinson's disease.” Annual Review of Pharmacology and
Toxicology, Vol.54, pp.141-164.
[15]. Greenamyre, J.T. (2000). “Chronic systemic pesticide
exposure reproduces features of Parkinson's disease.”
Nature Neuroscience, Vol.3, No.12, pp.1301-1306.
[16]. Isle of Man dementia rates rise over five years. (2014,
March 20). BBC.Retrieved March, 30, 2014, from
http://www.bbc.co.uk/news/world-europe-isle-of-man-
26647585
[17]. Jankovic, J (2008). “Parkinson's disease: Clinical
features and diagnosis.” Journal of Neurology,
Neurosurgery & Psychiatry, Vol.79, No.4, pp.368–76.
[18]. Kim, Y. D., Lantz-McPeak, S. M., Ali, S. F., Kleinman, M.
T., Choi, Y. S., & Kim, H. (2014). “Effects of ultrafine diesel
exhaust particles on oxidative stress generation and
dopamine metabolism in PC-12 cells.” Environmental
Toxicology and Pharmacology, Vol.37, No.3, pp.954-959.
[19]. Lewis, C., Annet, L., Davenport, S., Hall, A., & Lovatt, P.
(2014). “Mood changes following social dance sessions in
people with Parkinson's disease.” Journal of Health
Psychology. pp.1-10.
[20]. LeWitt, P.A., Rezai, A.I., Leehey, M.E., Ojemann, S.G.,
Flaherty, A.W., Eskandar, E. & et al. (2011). “AAV2-GAD
gene therapy for advanced Parkinson's disease: a double- blind, sham-surgery controlled, randomised trial.” The
Lancet Neurology. Vol.10, No.4, pp.309-19.
[21]. Kövari, E., Herrmann, F. R., Bouras, C., & Gold, G.
(2014). “Amyloid deposition is decreasing in ageing brains.”
Neurology, Vol.82, No.4, pp.326-331.
[22]. Lees, A.J., Hardy, J., Revesz, T. (2009). “Parkinson's
disease.” Lancet, Vol.373, No.9680, pp.2055-2066.
[23]. Louis, E.D., Michalec, M., Jiang, W., Factor-Litvak, P., &
Zheng, W. (2014). “Elevated blood harmane (1-methyl-9Hpyrido[
3,4-b]indole) concentrations in Parkinson's disease.”
NeuroToxicology, Vol.40, pp.52-56.
[24]. Ludwig, I.A. Clifford, M.N. Lean, M.E.J Ashihara, H. &
Crozier, A. (2014). Coffee: biochemistry and potential
impact on health, Food & Function.
[25]. Mapstone, M., Cheema, A.K., Fiandaca, M.S.,
Zhong, X., Mhyre, T.R., MacArthur, L.H., et al. (2014).
Plasma phospholipids identify antecedent memory
impairment in older adults, Nature Medicine.
[26]. Marras, C., Hincapié, C.A., Kristman, V.L.,
Cancelliere, C., Soklaridis, S., Li, A., et al. (2014).
“Systematic review of the risk of Parkinson's disease after
mild traumatic brain injury: Results of the international
collaboration on mild traumatic brain injury prognosis.”
Archives of Physical Medicine and Rehavilitation, Vol.95,
No.3, pp.238-244.
[27]. National Health Service (2012). Alzheimer's disease.
[28]. Pace-Shott,E.F. & Spencer, R.M.C. (2014). “Sleep loss
in older adults: Effects on waking performance and sleepdependent
memory consolidation with healthy aging and
insomnia.” Sleep Deprivation and Disease, pp.185-197.
[29]. Parsons, C.G., Danysz, W., Dekundy, A., & Pulte, I. (2013). “Memantine and Cholinesterase inhibitors:
Complementary mechanisms in the treatment of
Alzheimer's disease.” Neurotoxicity Research, Vol.24,
No.30, pp.358-369.
[30]. Quik, M., Huang, L.Z., Parameswaran, N., Bordia, T.,
Campos, C., Perez, X.A. (2009). “Multiples roles for nicotine
in Parkinson's disease.” Biochemical Pharmacology,
Vol.78, No.7, pp.677-685.
[31]. Rabey, J. M. &Hefti, F. (1990). “Neuromelanin synthesis
in rat and human substantianigra.” Journal of Neural
Transmission - Parkinson's Disease and Dementia Section,
Vol.2, No.1, pp.1–14
[32]. Reeve, A., Simcox, E, & Turnbull, D. (2014). “Ageing
and Parkinson's disease: Why is advancing age the biggest
factor?” Ageing Research Reviews, Vol.14, pp.19-30.
[33]. Sawmilller, D. Li, S., Shahaduzzaman, M, Smith, A.J.,
Obregon, D., Giuta, B., Borlongan, C.V. et al (2014).
Luteolin reduces Alzheimer's disease pathologies induced
by traumatic brain injury, Molecular Sciences.
[34]. Tsai, C., Huang, H, Liu, B., Li, C, Lu, M., Chen, X., et al.
(2014). “Activation of N-methyl-D-aspartate receptor
glycine site temporally ameliorates neuropsychiatric
symptoms of Parkinson's disease with dementia.” Psychiatry
and Clinical Neurosciences, Vol.68, No.9, pp.692-700.
[35]. Waldemar, G., Dubois, B., Emre, M., Georges, J.,
McKeith, I. G., Rossor, M., ...&Winblad, B. (2007).
“Recommendations for the diagnosis and management
of Alzheimer's disease and other disorders associated with
dementia: EFNS guideline.” European Journal of
Neurology, Vol.14, No.1, pp.1-26.
